Personalis and the Garvan Institute Partner
News Oct 22, 2014
Personalis, Inc. and the Garvan Institute of Medical Research in Sydney, Australia, will form a commercial partnership designed to bring together best-in-class solutions for high-quality, large-scale human whole genome sequencing, analysis and interpretation for researchers and clinicians, worldwide.
The Garvan Institute of Medical Research, one of Australia’s leading medical research institutions, created the first purpose-built facility in its country for undertaking large-scale clinical research projects and ultimately clinical-grade genome sequencing for diagnostic purposes.
“We are excited to enter into a partnership that will allow researchers and clinicians worldwide to leverage Garvan’s sophisticated sequencing expertise and large-scale sequencing platforms, and for all parties involved to benefit from Personalis’ sophisticated pipeline, analysis experience, and core infrastructure capabilities that have been expertly honed through the analysis of thousands of human genomes,” said John West, Chief Executive Officer at Personalis. “Whole human genome sequencing analysis can be daunting, complex and time-consuming. This agreement will accelerate the pace of scientific research and clinical diagnosis by facilitating rapid, comprehensive and accurate whole genome sequencing combined with high-quality analysis and easy-to-interpret reports for large projects involving human data.”
Associate Professor Marcel Dinger, Head of the Kinghorn Centre for Clinical Genomics at the Garvan Institute, added: “The expertise at Personalis in analyzing, annotating and interpreting human genome sequencing data and in designing human genome research studies for clinical diagnostics is first-class, and we are delighted to combine our world-class facilities in a way that will benefit researchers and clinicians worldwide.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE